August 2014 - Volume 24 - Issue 4 - Contributor Index

Alphabetical Search
I
N
U
Y
Author:
Alrwas, Anas

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic...

Alrwas, Anas; Papadopoulos, Nicholas E.; Cain, Suzanne; More

Melanoma Research . 24(4):342-348, August 2014.

Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma...

Mirjacic Martinovic, Katarina M.; Babovic, Nada Lj.; Džodic, Radan R.; More

Melanoma Research . 24(4):295-304, August 2014.

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic...

Alrwas, Anas; Papadopoulos, Nicholas E.; Cain, Suzanne; More

Melanoma Research . 24(4):342-348, August 2014.

Author:
Becker, Nils

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic...

Alrwas, Anas; Papadopoulos, Nicholas E.; Cain, Suzanne; More

Melanoma Research . 24(4):342-348, August 2014.

Increased risk of developing cutaneous malignant melanoma is associated with variation in pigmentation genes and VDR, and may involve epistatic effects

Kosiniak-Kamysz, Agnieszka; Marczakiewicz-Lustig, Anna; Marcinska, Magdalena; More

Melanoma Research . 24(4):388-396, August 2014.

Author:
Brice, Pauline
Author:
Cain, Suzanne

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic...

Alrwas, Anas; Papadopoulos, Nicholas E.; Cain, Suzanne; More

Melanoma Research . 24(4):342-348, August 2014.

Author:
Chan, Hee-Lam
Author:
Chen, Guilin
Author:
Chin, Melvin

Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma...

Mirjacic Martinovic, Katarina M.; Babovic, Nada Lj.; Džodic, Radan R.; More

Melanoma Research . 24(4):295-304, August 2014.

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic...

Alrwas, Anas; Papadopoulos, Nicholas E.; Cain, Suzanne; More

Melanoma Research . 24(4):342-348, August 2014.

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic...

Alrwas, Anas; Papadopoulos, Nicholas E.; Cain, Suzanne; More

Melanoma Research . 24(4):342-348, August 2014.

Author:
Dennis, Mike
Author:
Du, Ziwei
Author:
Eide, Melody J.
Author:
Fang, Zhengyu
Author:
Fusi, Alberto
Author:
Gao, Linda
Author:
Gero, Daniel
Author:
Halaban, Ruth
Author:
Hao, Yinghua
Author:
Hartmann, Arndt
Author:
He, Yanling
Author:
Hinek, Anna
Author:
Ho, Jonhan
Author:
Hwu, Patrick

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic...

Alrwas, Anas; Papadopoulos, Nicholas E.; Cain, Suzanne; More

Melanoma Research . 24(4):342-348, August 2014.

Author:
Hwu, Wen-Jen

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic...

Alrwas, Anas; Papadopoulos, Nicholas E.; Cain, Suzanne; More

Melanoma Research . 24(4):342-348, August 2014.

Author:
Jamal, Sumayah

Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma...

Mirjacic Martinovic, Katarina M.; Babovic, Nada Lj.; Džodic, Radan R.; More

Melanoma Research . 24(4):295-304, August 2014.

Author:
Kalia, Sunil
Author:
Kim, Kevin B.

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic...

Alrwas, Anas; Papadopoulos, Nicholas E.; Cain, Suzanne; More

Melanoma Research . 24(4):342-348, August 2014.

Author:
Kong, Yong

Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma...

Mirjacic Martinovic, Katarina M.; Babovic, Nada Lj.; Džodic, Radan R.; More

Melanoma Research . 24(4):295-304, August 2014.

Increased risk of developing cutaneous malignant melanoma is associated with variation in pigmentation genes and VDR, and may involve epistatic effects

Kosiniak-Kamysz, Agnieszka; Marczakiewicz-Lustig, Anna; Marcinska, Magdalena; More

Melanoma Research . 24(4):388-396, August 2014.

Author:
Lebbé, Celeste
Author:
Lee, Tim K.
Author:
Li, Bin
Author:
Li, Yanyan
Author:
Lorigan, Paul
Author:
Mak, Gabriel

Increased risk of developing cutaneous malignant melanoma is associated with variation in pigmentation genes and VDR, and may involve epistatic effects

Kosiniak-Kamysz, Agnieszka; Marczakiewicz-Lustig, Anna; Marcinska, Magdalena; More

Melanoma Research . 24(4):388-396, August 2014.

Increased risk of developing cutaneous malignant melanoma is associated with variation in pigmentation genes and VDR, and may involve epistatic effects

Kosiniak-Kamysz, Agnieszka; Marczakiewicz-Lustig, Anna; Marcinska, Magdalena; More

Melanoma Research . 24(4):388-396, August 2014.

Author:
Matter, Maurice

Decreased expression of NKG2D, NKp46, DNAM-1 receptors, and intracellular perforin and STAT-1 effector molecules in NK cells and their dim and bright subsets in metastatic melanoma...

Mirjacic Martinovic, Katarina M.; Babovic, Nada Lj.; Džodic, Radan R.; More

Melanoma Research . 24(4):295-304, August 2014.

Author:
Mourah, Samia
Author:
Osio, Amélie
Author:
Out, Jacoba J.
Author:
Pages, Cécile
Author:
Pagès, Cécile

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic...

Alrwas, Anas; Papadopoulos, Nicholas E.; Cain, Suzanne; More

Melanoma Research . 24(4):342-348, August 2014.

Author:
Patel, Sapna P.

Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with metastatic...

Alrwas, Anas; Papadopoulos, Nicholas E.; Cain, Suzanne; More

Melanoma Research . 24(4):342-348, August 2014.

Author:
Pigozzo, Jacopo

Increased risk of developing cutaneous malignant melanoma is associated with variation in pigmentation genes and VDR, and may involve epistatic effects

Kosiniak-Kamysz, Agnieszka; Marczakiewicz-Lustig, Anna; Marcinska, Magdalena; More

Melanoma Research . 24(4):388-396, August 2014.

Author:
Rossi, Carlo R.
Author:
Roux, Jennifer
Author:
Sadoux, Aurelie
1 2 Next